News
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...
A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...
22h
GlobalData on MSNNovo Nordisk ramps up obesity fight, advances amycretin to Phase IIINovo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...
19h
Zacks.com on MSNNVO Stock up on Plans to Advance Obesity Candidate AmycretinDetailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results